The lead company in the use of TCR-engineered T-cell therapy to treat cancer, Adaptimmune Therapeutics PLC (NASDAQ:ADAP) will be the main host of a live webcast which will be held alongside the 2016 Analyst and Investor Day. The event which will take place in New York, NY will have a live audio webcast and the additional slide presentation which will be made accessible through the investor section of the company’s website.
A replay will also be obtainable from the company’s website but for only 30 days after the event.
The clinical stage biopharmaceutical company’s focus is on innovative cancer immunotherapy products based on its T-cell receptor (TCR) platform. Cancer, which is characterized by the uncontrolled growth of abnormal cells, is a leading cause of death worldwide. Adaptimmune is trying to utilize the body’s own T-cells to target and kill cancer cells through the use of increased affinity TCRs. They can potentially aid in strengthening natural patient T-cell responses.
The NY-ESO cancer antigen is the main target of Adaptimmune’s lead program which is an affinity-enhanced T-cell therapy. Already there are positive results of efficacy and tolerability from NY-ESO TCR affinity enhanced T-cell therapy whose Phase 1/2 trials in solid tumors and in hematologic cancer types are ongoing.
Purposes of development and commercialization of the NY-ESO TCR program, Adaptimmune has embraced a strategic collaboration and licensing agreement with GlaxoSmithKline plc (NYSE:GSK) which is expected to heighten the addition of target peptides.
The collaboration which was announced in February 2016 will give GSK various mandates like the nomination of four additional target peptides apart from the NY-ESO TCR therapeutic candidate. However, Adaptimmune is already having a number of proprietary programs besides the identification of over 30 intracellular target peptides.
GSK will also be allowed to nominate one TCR therapeutic candidate while Adaptimmune will hold onto all other rights of the other two TCR therapeutic candidates.